Bernhard Ludvik
Overview
Explore the profile of Bernhard Ludvik including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
111
Citations
2127
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Forst T, De Block C, Del Prato S, Frias J, Lautenbach A, Ludvik B, et al.
Diabetes Obes Metab
. 2025 Feb;
PMID: 39931897
Obesity and type 2 diabetes mellitus (T2D) are widespread diseases that significantly impact cardiovascular and renal morbidity and mortality. In the recent years, intensive research has been performed to assess...
2.
Bonaca M, Catarig A, Hansen Y, Houlind K, Ramesh C, Ludvik B, et al.
Eur Heart J Cardiovasc Pharmacother
. 2024 Oct;
10(8):728-737.
PMID: 39424598
Background: People with lower extremity peripheral artery disease (PAD) suffer from a high burden of symptoms and significant functional impairment. There are few therapies that improve function and reduce symptoms...
3.
Sourij H, Azhar K, Aziz F, Kojzar H, Sourij C, Fasching P, et al.
Diabetes Obes Metab
. 2024 Oct;
27(1):111-122.
PMID: 39359208
Aims: This study assessed the achievement rates of metabolic risk factor targets and their association with clinical characteristics and comorbidities among individuals with type 2 diabetes (T2D) treated in the...
4.
Forst T, De Block C, Del Prato S, Armani S, Frias J, Lautenbach A, et al.
Diabetes Obes Metab
. 2024 Jul;
26(10):4178-4196.
PMID: 39072877
Introdroduction: Obesity and its associated metabolic conditions have become a significant global health problem in recent years, with many people living with obesity fulfilling criteria for pharmacological treatment. The development...
5.
Parzer V, Taube M, Ludvik B, Peltonen M, Svensson P, Brix J, et al.
Obes Facts
. 2023 Nov;
17(1):81-89.
PMID: 38035550
Introduction: Body size underestimation in patients with obesity may be associated with long-term weight increase. In the current report, we analyse changes in body size perception in patients with obesity...
6.
Brix J, Andersen B, Aydinkoc-Tuzcu K, Beckerhinn P, Brossard-Eitzinger A, Cavini A, et al.
Wien Klin Wochenschr
. 2023 Oct;
135(Suppl 6):706-720.
PMID: 37821694
The prevalence of overweight and obesity is steadily increasing in Austria as well as internationally. Obesity in particular is associated with multiple health risks, comorbidities, functional disability, and social stigma....
7.
Toplak H, Bilitou A, Alber H, Auer J, Clodi M, Ebenbichler C, et al.
Wien Klin Wochenschr
. 2023 Jun;
135(13-14):364-374.
PMID: 37286910
Objective: The low-density lipoprotein cholesterol goals in the 2019 European Society of Cardiology/European Atherosclerosis Society dyslipidaemia guidelines necessitate greater use of combination therapies. We describe a real-world cohort of patients...
8.
Kietaibl A, Huber J, Clodi M, Abrahamian H, Ludvik B, Fasching P
Wien Klin Wochenschr
. 2023 Apr;
135(Suppl 1):256-271.
PMID: 37101047
This position statement reflects the perspective of the Austrian Diabetes Association concerning the perioperative management of people with diabetes mellitus based on the available scientific evidence. The paper covers necessary...
9.
Weitgasser R, Ciardi C, Traub J, Barta M, Riedl M, Clodi M, et al.
Wien Klin Wochenschr
. 2023 Apr;
135(Suppl 1):137-142.
PMID: 37101034
Diabetes education and self-management play a critical role in diabetes care. Patient empowerment aims to actively influence the course of the disease by self-monitoring and subsequent treatment modification as well...
10.
Lechleitner M, Kaser S, Hoppichler F, Roden M, Weitgasser R, Ludvik B, et al.
Wien Klin Wochenschr
. 2023 Apr;
135(Suppl 1):98-105.
PMID: 37101030
This guideline summarizes diagnosis of type 1 diabetes, including accompanying autoimmune disorders, insulin therapy regimens and glycemic target values.